RxCelerate is the perfect partner for virtual, asset-centric companies. If you locate an asset (perhaps in academia or out-licensed from a pharma company) the quickest and cheapest route to the clinic is with RxCelerate.

We can deliver the entire programme of GLP toxicology, ADME and efficacy studies in state of the art preclinical models of disease to secure an investigational new drug (IND) approval to begin clinical trials. Typically, for small molecule candidates such a programme can be executed with RxCelerate in under 12 months.

RxCelerate is the perfect partner for larger drug development companies. If you are developing a drug candidate in-house, but need to out-source specific elements of the programme, RxCelerate offers world-leading capabilities in preclinical efficacy studies, toxicology and ADME to supplement your internal skillset.

Our philosophy is to eliminate compromises: to deliver more high quality data, quicker and at lower cost. The economics of drug development only make sense if you can rapidly de-risk preclinical candidates at low cost.

Uniquely, RxCelerate offers combination study designs, investigating efficacy, toxicology and ADME in a single experiment – providing more insight per dollar than conventional approaches.

We take industry-standard preclinical disease models, and improve them by adding additional end-points. A smarter approach means more data, quicker and at lower cost.